Abstract
Ensuring the consistent safety and efficacy of a vaccine has long been recognized as an essential element in a successful disease-control program. Indeed, the development of appropriate laboratory methods to characterize a vaccine with respect to its component antigens, safety, and potency must be a prerequisite to the routine clinical use of any new bacterial, viral, or antiparasite vaccines, Adequate control measures serve to safeguard vaccinees both against unacceptable adverse effects and inadequate protection.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
(1992) Guldehnes for national authorities on quality assurance for biological products. WHO Techmcal Report Series 822, 31–46.
Griffiths, E. (1988) Efficacy of whole-cell pertussis vaccine, in Pathogenesis and Immunity in Pertussis (Wardlaw, A. C. and Parton R., eds.), Wiley, Chichester, pp. 353–374.
Leslie, P. H. and Gardner, A. D. (1931) The phases of Haemophilus pertussu. J. Hygiene 31, 423–434
(1990) Requirements for poliomyelitis vaccine (oral). part C: requirements for poliomyelitis vaccine (oral) prepared in primary cultures of monkey kidney cells. WHO Technical Report Series 800, 30–86.
(1994) Requirements for measles, mumps and rubella vaccines and combined vaccine (live): appendix 2-requirements for human dlplold cells used for the production of measles, mumps and rubella vaccme. WHO Technical Report Series 840, 100–201.
(1987) Requirements for continuous cell lines used for blologicals production. WHO Technxal Report Series 745 93–107.
(1987) Acceptability of cell substrates for production of biologicals. WHO Technical Report Series, vol. 747.
Schneider, L. G. (1995) Rabies virus vaccines in non-target effects of live vaccines. Devel. Biol. Standard. 84, 49–54.
Robertson, J. S. (1994) Safety considerations for nucleic acid vaccmes. Vaccine 12, 1526–1528.
Smith, H A. (1994) Regulatory considerations for nucleic acid vaccmes. Vaccine 12, 1515–1519.
(1994) Guidance for industry for the submission of chemistry, manufacturing and controls information for synthetic peptide substances. Center for Drug Evaluation and Research, and Center for Biologlcs Evaluation and Research, Food and Drug Admmistration, Washington, DC.
(1992) Good manufacturing practices for biological products. WHO Technical Report Series 822, 20–30.
Dobbelaer, R. (1994) The system of mutual recogmtion of batch release in the EU-implications for combined vaccines. Biologlcals 22, 377–380
(1995) WHO guidelines for good clmical practice (GCP) for trials on pharmaceutical products. WHO Technical Report Series 850, 97–137.
(1995) Manual of laboratory methods for potency testing of vaccmes used in the WHO Expanded Programme on Immunization: World Health Organization. WHO/BLG/95.1.
Diaz-Ortega, J. L., Forsey, T., Clements, J., and Milstien, J. (1994) The relationstip between dose and response of standard measles vaccmes. Biologxals 22, 35–44.
Egan, W., Frasch, C., and Anthony, B. F. (1995) Lot-release criteria, post licensure quality control and the Haemophilus injluenzae Type b conjugate vaccmes. JAMA 273, 888,889.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Humana Press Inc, Totowa, NJ
About this protocol
Cite this protocol
Griffiths, E. (1996). Assuring the Quality of Vaccines. In: Robinson, A., Farrar, G.H., Wiblin, C.N. (eds) Vaccine Protocols. Methods in Molecular Medicine™, vol 4. Humana Press. https://doi.org/10.1385/0-89603-334-1:269
Download citation
DOI: https://doi.org/10.1385/0-89603-334-1:269
Publisher Name: Humana Press
Print ISBN: 978-0-89603-334-4
Online ISBN: 978-1-59259-588-4
eBook Packages: Springer Protocols